Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,376 JPY | +1.25% | +2.38% | -6.21% |
Jun. 25 | Japanese Shares Close Higher as Officials Address Yen Volatility Concerns | MT |
Jun. 25 | Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.21% | 11.11B | A- | ||
+58.90% | 827B | C+ | ||
+38.38% | 634B | B | ||
-6.47% | 350B | C+ | ||
+15.42% | 319B | B- | ||
+8.27% | 294B | C+ | ||
+12.93% | 240B | B+ | ||
+14.73% | 221B | B- | ||
-0.04% | 219B | A+ | ||
+8.40% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4507 Stock
- Ratings Shionogi & Co., Ltd.